Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 15 03 2023
accepted: 10 05 2023
medline: 3 7 2023
pubmed: 29 6 2023
entrez: 29 6 2023
Statut: epublish

Résumé

Vaccination strategies aimed at maturing broadly neutralizing antibodies (bnAbs) from naïve precursors are hindered by unusual features that characterize these Abs, including insertions and deletions (indels). Longitudinal studies of natural HIV infection cases shed light on the complex processes underlying bnAb development and have suggested a role for superinfection as a potential enhancer of neutralization breadth. Here we describe the development of a potent bnAb lineage that was elicited by two founder viruses to inform vaccine design. The V3-glycan targeting bnAb lineage (PC39-1) was isolated from subtype C-infected IAVI Protocol C elite neutralizer, donor PC39, and is defined by the presence of multiple independent insertions in CDRH1 that range from 1-11 amino acids in length. Memory B cell members of this lineage are predominantly atypical in phenotype yet also span the class-switched and antibody-secreting cell compartments. Development of neutralization breadth occurred concomitantly with extensive recombination between founder viruses before each virus separated into two distinct population "arms" that evolved independently to escape the PC39-1 lineage. Ab crystal structures show an extended CDRH1 that can help stabilize the CDRH3. Overall, these findings suggest that early exposure of the humoral system to multiple related Env molecules could promote the induction of bnAbs by focusing Ab responses to conserved epitopes.

Identifiants

pubmed: 37384622
doi: 10.1371/journal.ppat.1011416
pii: PPATHOGENS-D-23-00486
pmc: PMC10309625
doi:

Substances chimiques

Broadly Neutralizing Antibodies 0
HIV Antibodies 0
Epitopes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1011416

Informations de copyright

Copyright: © 2023 Joyce et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell Rep. 2018 Jun 12;23(11):3249-3261
pubmed: 29898396
Cell Host Microbe. 2018 Oct 10;24(4):593-599.e3
pubmed: 30269971
Nat Commun. 2019 May 16;10(1):2190
pubmed: 31097697
Curr Opin Immunol. 2018 Aug;53:209-216
pubmed: 30190230
Nature. 2022 Sep;609(7929):998-1004
pubmed: 36131022
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
Nat Med. 2019 Apr;25(4):547-553
pubmed: 30936546
Virus Evol. 2019 Nov 04;5(2):vez044
pubmed: 31700680
Adv Immunol. 2019;143:11-73
pubmed: 31607367
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
AIDS. 2009 Mar 13;23(5):579-87
pubmed: 19516110
Immunity. 2016 May 17;44(5):1215-26
pubmed: 27192579
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
pubmed: 12644702
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
J Virol. 2010 Sep;84(18):9415-26
pubmed: 20631143
J Clin Invest. 2001 Oct;108(7):1061-70
pubmed: 11581307
PLoS Pathog. 2016 Jan 14;12(1):e1005369
pubmed: 26766578
J Virol. 2009 Jul;83(14):7337-48
pubmed: 19439467
PLoS Pathog. 2012;8(3):e1002611
pubmed: 22479183
Sci Transl Med. 2019 Oct 30;11(516):
pubmed: 31666399
BMC Bioinformatics. 2010 Jan 13;11:24
pubmed: 20070885
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7039-E7048
pubmed: 27791170
Virus Evol. 2016 Jul 08;2(2):vew018
pubmed: 29492273
Cell Host Microbe. 2017 Aug 9;22(2):207-216
pubmed: 28799906
Nat Rev Immunol. 2002 Sep;2(9):706-13
pubmed: 12209139
Biochem Biophys Res Commun. 2009 Dec 18;390(3):404-9
pubmed: 19748484
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100831
Cell. 2013 Mar 28;153(1):126-38
pubmed: 23540694
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973404
Cell Host Microbe. 2014 Sep 10;16(3):304-13
pubmed: 25211073
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
Nat Rev Immunol. 2023 Mar;23(3):142-158
pubmed: 35962033
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):1-11
pubmed: 17514017
Curr Opin HIV AIDS. 2019 Jul;14(4):286-293
pubmed: 30994504
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2567-75
pubmed: 24821781
Phys Rev E. 2021 May;103(5-1):052408
pubmed: 34134229
Cell Rep. 2021 Feb 9;34(6):108684
pubmed: 33567273
Immunol Rev. 2017 Jan;275(1):161-182
pubmed: 28133806
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17033-8
pubmed: 15563589
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Cell Rep. 2018 Apr 17;23(3):682-691
pubmed: 29669274
Sci Rep. 2016 Apr 22;6:23901
pubmed: 27102563
Structure. 2015 Oct 6;23(10):1943-1951
pubmed: 26388028
AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1135-1142
pubmed: 26910384
Cell. 2016 Apr 7;165(2):449-63
pubmed: 26949186
Cell Immunol. 2017 Nov;321:18-25
pubmed: 28735813
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
PLoS One. 2012;7(4):e35356
pubmed: 22530008
BMC Bioinformatics. 2012 Feb 14;13:31
pubmed: 22333067
Nat Immunol. 2020 Feb;21(2):199-209
pubmed: 31959979
J Virol. 2009 Jan;83(2):1045-59
pubmed: 19004942
Science. 2012 Jul 13;337(6091):183-6
pubmed: 22798606
Immunity. 2022 Nov 8;55(11):2168-2186.e6
pubmed: 36179690
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2529-33
pubmed: 7708679
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9
pubmed: 25422458
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298420
Retrovirology. 2018 Sep 5;15(1):61
pubmed: 30185183
J Immunol. 1992 Oct 1;149(7):2337-44
pubmed: 1382098
Immunity. 2016 Jul 19;45(1):31-45
pubmed: 27438765
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
Cell. 2014 Jul 31;158(3):481-91
pubmed: 25065977
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23
pubmed: 9294155
Sci Rep. 2020 Jan 24;10(1):1120
pubmed: 31980672
Curr Opin Immunol. 2016 Oct;42:83-90
pubmed: 27343703
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Cold Spring Harb Protoc. 2011 Jun 01;2011(6):695-715
pubmed: 21632778
Immunity. 2017 Nov 21;47(5):990-1003.e9
pubmed: 29166592
J Clin Invest. 2005 Nov;115(11):3205-16
pubmed: 16211091
Bioinformatics. 2015 Nov 15;31(22):3718-20
pubmed: 26209431
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
Immunity. 2019 Mar 19;50(3):677-691.e13
pubmed: 30876875
Genes Immun. 2012 Oct;13(7):523-9
pubmed: 22717702
Elife. 2021 Jul 15;10:
pubmed: 34263727
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77
pubmed: 23115339
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
Science. 2019 Dec 6;366(6470):
pubmed: 31672916
Immunol Rev. 2017 Jan;275(1):203-216
pubmed: 28133796
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
J Exp Med. 2013 Apr 8;210(4):655-63
pubmed: 23530120
Science. 2022 May 13;376(6594):eabl5197
pubmed: 35549406
Cell Rep. 2015 Jun 16;11(10):1604-13
pubmed: 26051934
NPJ Vaccines. 2021 Sep 6;6(1):113
pubmed: 34489473
Bioinformatics. 2020 Feb 1;36(3):964-965
pubmed: 31400197
Nat Biotechnol. 2012 May 07;30(5):423-33
pubmed: 22565972
J Virol. 2005 Aug;79(16):10701-8
pubmed: 16051862
Cell Rep. 2016 Mar 22;14(11):2695-706
pubmed: 26972002
Cell Host Microbe. 2012 Oct 18;12(4):396-407
pubmed: 23084910
J Virol. 2010 Oct;84(20):10510-21
pubmed: 20686044
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
Nat Med. 2015 Nov;21(11):1332-6
pubmed: 26457756
J Virol. 2014 Mar;88(5):2645-57
pubmed: 24352455
J Exp Med. 2016 Apr 4;213(4):469-81
pubmed: 27022144
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20077-20087
pubmed: 32747563
PLoS Pathog. 2022 Mar 18;18(3):e1010369
pubmed: 35303045
Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11):
pubmed: 28159875
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
Cell. 2016 Jun 30;166(1):77-87
pubmed: 27345369
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
J Immunol. 1991 Jun 15;146(12):4385-91
pubmed: 1710250
Immunity. 2019 Jul 16;51(1):141-154.e6
pubmed: 31315032

Auteurs

Collin Joyce (C)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.

Sasha Murrell (S)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.

Ben Murrell (B)

Department of Medicine, University of California San Diego, San Diego, California, United States of America.
Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden.

Oluwarotimi Omorodion (O)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.

Lorena S Ver (LS)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Nancy Carrico (N)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Raiza Bastidas (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.

Rebecca Nedellec (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.

Michael Bick (M)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.

Jordan Woehl (J)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Fangzhu Zhao (F)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.

Alison Burns (A)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Shawn Barman (S)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Michael Appel (M)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Alejandra Ramos (A)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Lalinda Wickramasinghe (L)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Kemal Eren (K)

Department of Medicine, University of California San Diego, San Diego, California, United States of America.

Thomas Vollbrecht (T)

Department of Medicine, University of California San Diego, San Diego, California, United States of America.
Veterans Affairs San Diego Healthcare System, San Diego, California, United States of America.

Davey M Smith (DM)

Department of Medicine, University of California San Diego, San Diego, California, United States of America.

Sergei L Kosakovsky Pond (SL)

Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.

Ryan McBride (R)

Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States of America.

Charli Worth (C)

Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States of America.

Facundo Batista (F)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.

Devin Sok (D)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Pascal Poignard (P)

Institut de Biologie Structurale, Université Grenoble Alpes, Commissariat à l'Energie Atomique, Centre National de Recherche Scientifique and Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Bryan Briney (B)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, California, United States of America.

Ian A Wilson (IA)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America.

Elise Landais (E)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
IAVI, New York, New York, United States of America.

Dennis R Burton (DR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH